Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.
Issue is that longer run pipeline is coming to an end. The quest is always for the next big drug out there. Trying to buy Allergan, whose big thing is botox. Political pressure on lower drug prices. Monster yield of over 6.5%.
Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)
Good news, bad news. Dividend is beautiful, Q1 beat, cheap valuation, raised outlook for 2019. Problem is it's really levered to Humira, so a one-trick pony. Trying to buy Allergan to diversify. Likes it at a lower level, but cautious. Not really for an RRSP. (Analysts’ price target is $83.70)
Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.
Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.
